Twenty-nine B cell follicular lymphoma (FL) patients had their BM (n ‫؍‬ 12) or PBPC (n ‫؍‬ 17) purged using a panel of monoclonal antibodies and immunomagnetic beads (IMB). The median recovery of nucleated cells (NC) and CD34
Additionally, by applying sensitive detection techniques, lymphoma cells can be detected in histologically normal BM grafts in 20-70% of patients after high-dose therapy as well as in PBPC after mobilization. [6] [7] [8] [9] [10] The contribution of these graft contaminating malignant cells to relapse after transplantation remains controversial. Nevertheless, genemarking studies of autografted cells have shown that tumor cells remaining in the graft contribute to relapse. 11, 12 Another indirect line of evidence has been reported by Sharp et al 13 in lymphoma patients who had their marrows studied in vitro utilizing a tumor cell culture method. Those patients in whom lymphoma cells could be detected had a poorer survival than patients autografted with marrow in which tumor cells could not be grown in culture. Another report from the Dana-Faber Cancer Institute in patients with FLs has shown that efficient BM purging, evaluated by a PCR technique, improved the disease-free survival. 14 Consequently, a number of attempts have been made to treat the graft ex vivo with a variety of methods including chemotherapeutic or immunological agents. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Monoclonal antibodies (MoAb) can be used in different ways; one of them is the immunomagnetic technique where a combination with iron-containing polymer beads coated with a secondary polyclonal Ab is used. Afterwards, immunomagnetic beads (IMB)-target cell complexes can be separated by exposing the cell suspension to a magnetic field. This method has been used to purge grafts from patients with acute lymphoblastic leukemia (ALL), 17 neuroblastoma, 18 non-Hodgkin's lymphomas, 19 multiple myeloma 20 and some non-hematological tumors. 21 In this work, we report our experience on purging of lymphoma cells from BM and PBPC, using a panel of MoAb and IMB following a technique first developed by Kvalheim et al. 22, 23 The main parameters analyzed were effectiveness of lymphoma cell purging, nucleated and progenitor cell recovery and hematopoietic engraftment after autologous transplantation, comparing BM and PBPC.
Patients and methods

Patients
Twenty-nine patients with FL were enrolled in this study from June 1994 until February 1998. Thirteen were female and 16 male with a median age of 43 years (range . Until October 1995 purging was performed on BM harvests. Subsequently, PBPC harvests were used unless the initial cellularity was insufficient for purging. Twelve patients were eligible for BM and 17 for PBPC purging. BM biopsies and aspirations were performed at the time of evaluation and before purging. Only patients with less than 20% B lymphocyte BM infiltration after induction or salvage therapy were eligible for purging. Before purging, nine patients had detectable B cells (median 5%, range [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] in BM aspirates. The bcl2/IgH rearrangement status of the BM samples was known in 10 patients at diagnosis or at the time of evaluation and nine of them were positive. Nineteen patients were in first or subsequent CR, nine in partial remission (PR) and one in relapse.
BM and PBPC harvest and immunomagnetic purging
BM: At least 2 × 10 8 /kg body weight nucleated cells (NC) were collected in BM harvests. BM purging was performed according to an indirect immunomagnetic method previously described by Kvalheim et al 22 with some modifications. The working buffer used consisted of 0.9% sodium chloride (Baxter, Deerfield, IL, USA) containing 1% (w/v) human serum albumin (HSA, Grifols, Barcelona, Spain) and 1% (v/v) sodium bicarbonate (Pharmacia Iberica, Spain). Light-density mononuclear cells (LDCs) were isolated using Ficoll-Hypaque (1.077 g/ml; Pharmacia, Uppsala, Sweden) in a Cobe 2991 cell processor (Cobe BCT, Lakewood, CO, USA). 25 When the cellularity obtained after Ficoll isolation was higher than 4 × 10 7 LDCs/kg body weight, a fraction of 1 × 10 7 LDCs/kg was cryopreserved as a back-up. LDCs were incubated at a concentration of 2-3 × 10 7 cells/ml with a pool of GMP clinical grade B cell Ab (CD19, CD20, CD22, CD23 and CD37, Baxter Europe, Unterschleissheim, Germany), 1 mg of each, at 4°C for 30 min with gentle shaking. Cells were washed twice and resuspended to a final concentration of approximately 5 × 10 7 cells/ml in a Lifecell bag (Baxter). A sample was taken out to calculate the percentage of target cells. Cells were incubated for two rounds with previously washed IMB coated with sheep antimouse immunoglobulin (SAM-IMB, Dynabeads M-450; Dynal, Oslo, Norway) to give a SAM-IMB/target cell ratio of 20:1, which had been found to be optimal in preclinical experiments (data not shown). The cell suspension was incubated at 4°C for 30 min with gentle shaking. Separation of IMB-target cell complexes was performed by using the MaxSep Magnetic Cell Separator (Baxter) according to the manufacturer's instructions.
PBPC: PBPC were collected after different chemotherapy mobilization regimens (IAPVP-16: ifosfamide 5 g/m 2 i.v. day 1, VP-16 100 mg/m 2 i.v. days 1-3, Ara-C 1.2 g/m 2 /12 h i.v. days 1-2, methylprednisolone 80 mg/m 2 i.v. days 1-5 (n = 7) or cyclophosphamide 1.5 g/m 2 day 1 i.v. (n = 10)) followed by recombinant human G-CSF, administered s.c. at a daily dose of 5-10 g/kg/day starting the day after the completion of chemotherapy. Leukapheresis (LK) was initiated at a CD34 + cell count Ͼ2.5 × 10 6 /l. All collections were performed using the COBE Spectra (COBE) or CS3000 (Fenwal, Baxter Healthcare The different purging protocols applied on BM and PBPC were based on the different cellular composition between both sources of progenitors and no obvious influence on the purging results was noted.
Cell viability was evaluated by Trypan Blue dye exclusion in fresh and purged products. All cell counts during the procedure were obtained using a Coulter JT3 counter (Coulter Electronic, Hialeah, FL, USA).
Monoclonal Ab
The following GMP clinical grade Ab were used in this study: HD237 (IgG2b k , with specificity for CD19), L-3b3 k (IgG1, anti-CD20), HD239 (IgG2b k , anti-CD22), HD50 (IgG2b k , anti-CD23) and HD28 (IgG2a k , anti-CD37). These Ab were purchased by Baxter (Baxter Europe, Unterschleissheim, Germany). In 9/29 pool of four MoAb was used for transient supply problems.
Cytometry analysis
A sample of BM-LDCs or LK was taken out before purging and after the first and second round of incubation. The PE-CD34 (HPCA-2; IgG1, Becton Dickinson, San Jose, CA, USA) was used to assess the percentage of CD34-positive cells pre-and post-purging. Indirect immunofluorescence studies were performed to assess the percentage of target cells at each step during the treatment. Cell samples (5 × 10 5 cells) with surface-bound primary MoAb (those used for the immunomagnetic purging) were incubated with fluorescein isothiocyanate (FITC) goat-anti-mouse polyclonal Ab (Gam-FITC; Dako, Glostrup, Denmark). Double staining with PE-CD34 and Gam-FITC was performed before and after purging to assess the percentage of CD34 + cells that co-expressed target-positive cells. Markers of cell viability, propidium iodide (IP; Sigma Chemical, Saint Louis, MO, USA) or 7-aminoactinomycin-D (7-AAD; Molecular Probes, Eugene, OR, USA) were also included. Cells incubated with the nonbinding isotype Ab were used as controls to define the nonlabeled population. Erythrocytes were lysed from a sample using ammonium chloride lysis. A gate identifying CD34
+ cells was drawn in a dual-parameter cytogram of side scatter (SS) and fluorescence after excluding dead cells. Similarly, positive events with lymphoid morphology (as defined by SS) above the negative control were considered as target-positive cells. FS, SS (linear amplification) and fluorescence signals (logarithmic amplification) were determined for each cell and stored in list mode data files. Flow cytometry was performed on an Epics-XL-MCL cytometer (Coulter Electronic) equipped with 488 nm excitation argon laser.
Clonogenic assays
Clonogenic assays were performed in the LDCs-BM and PBPC cells before and after purging. For patients enrolled before 1997, cells were cultured in 0.9% methylcellulose (Sigma, Renfrewshire, UK) in IMDM (Gibco, Life Technologies, Paisley, UK) supplemented with 30% FBS (Gibco, Life Technologies), 1% deionizated BSA (Sigma Chemical) with 2 mm l-glutamine, 2-ME (Merk) 10 −4 m, 2 U/ml of rh-erythropoietin (Boehringer Mannheim, Mannheim, Germany), 100 ng/ml of rh-GM-CSF (Boehringer Mannheim) and 10 ng/ml of rh-IL-3 (Sandoz, Vienna, Austria). After 1997, a commercially prepared methylcellulose-based medium with rh-SCF, rh-IL-3, rh-GM-CSF and rh-erythropoietin (Stem Cell Technologies, Vancouver, Canada) was used. Assays were run in triplicate. Cells were plated at 10 5 cells/ml. Cultures were incubated at 37°C and 5% CO 2 . Colonies were enumerated using an inverted microscope after 12-14 days of culture.
DNA preparation and PCR amplification
DNA was isolated by classical techniques (proteinase-K digestion and phenol chloroform extraction). 26 For samples attached to IMB a magnetic field was applied before phenol extraction in order to remove the beads. PCR amplification of the t(14;18) bcl-2/IgH rearrangement was undertaken in the presence of 1 g of genomic DNA, 67 mm Tris-HCl (pH 8.8), 16.6 mm (NH 4 ) 2 SO 4 , 0.01% Tween-20, 2.5 mm MgCl 2 , 0.2 mm dNTPs, 25 pmol oligonucleotide primers specific for the MBR region of the bcl2 gene (5′-CCTTTA-GAGAGTTGCTTTACGTG-3′) and the JH segments of the IgH gene (5′-ACCTGAGGAGACGGTGACC-3′) 27 and 1 U Taq polymerase (DNA-Polymerase-C; Bio 101, La Jolla, CA, USA) in a total volume of 50 l. Amplification was performed for 35 cycles on a Hybaid (Teddington, Middlesex, UK) apparatus with the following protocol: 1 min at 94°C, 1 min at 65°C and 1 min at 72°C increased to 10 min in the last cycle. To ensure that DNA could be amplified in all samples, a 172 bp fragment of the unrearranged bcl2 gene was amplified using the 5′-GGAGGTCTGGCTTCATAC-3′ primer and the MBR primer specified above, under the same conditions. 10 l of PCR amplified products were separated on a 1.5% agarose gel, transferred to a nylon membrane (Hybond-N; Amersham, Buckinghamshire, UK) and hybridized with an internal 32 P-bcl2 probe (5′-GGCCTGTTTCAACACA-GACCC-3′) labeled with T4 polynucleotide kinase (Pharmacia) according to the manufacturer's instructions.
The sensitivity of the analysis was estimated by concurrent amplification of log dilutions of Karpas 422 cells (a bcl-2/IgH rearranged cell line obtained from the ATCC) in normal cells (buffy coat cells from healthy donors) which proved to be 10
.
Purging efficiency
The specific cell depletion yield was determined using the following formula: depletion [log] = log 10 (total positive cells pre-purging/total positive cells post-purging). Total positive cells were obtained by multiplying the percentage of lymphoid-GamFITC-positive cells by the cell count and volume of the specimen.
Purging efficiency was monitored by determining the reduction in the total number of target antigen-positive cells, including normal B and lymphoma cells. In addition, using an established cell line, the limit for sensitivity detection of cells by flow cytometry was set at 0.1%. When positive cells were not detectable in the final product, the target cell contamination was considered to be less than 0.1%.
Nonspecific cell loss was calculated by the difference between cell loss shown during the purging procedure and cell loss due to specific (target) cell removal.
Cryopreservation, storage and infusion
Purged LDCs-BM or PBPC were concentrated by centrifugation and resuspended in 50 ml of PBS. An equal volume of cryopreservation solution consisting of 20% dimethylsulfoxide (DMSO, Sigma Chemical, Irvine, UK) and 8% HSA in PBS was added to achieve a final DMSO and HSA of 10% and 4%, respectively. Cells were then cooled in a programmed freezer following standard procedures and stored in liquid N 2 until reinfusion. Unpurged LDCS-BM or PBPC saved as back-up were cryopreserved in autologous plasma and DMSO (10%) and stored in the same conditions. On the day of infusion, bags were thawed in a 37°C water bath. Bag contents were aspirated into 60 ml syringes and injected through a central venous catheter. A sample was obtained after thawing for cell counts and hematopoietic progenitor cell culture.
Conditioning regimen
All patients received cyclophosphamide (60 mg/kg i.v. 2 consecutive days) plus hyperfractionated TBI (2-2.5 Gy per fraction, twice daily on 3 consecutive days), as the conditioning regimen.
Statistical analysis
Data are shown as median and range. Statistical analysis in SPSS 7.5 software was performed using the Wilcoxon rank test and Spearman coefficient correlation. Time-dependent variables were compared between the two groups using the log rank test. A P value lower than 0.05 was considered significant.
Results
BM and PBPC processing
Results of the purging procedures are shown in Table 1 . PBPC: A median of two LK per patient (range 1-4) was performed. A cellular fraction of 2 × 10 6 CD34 + /kg was taken out and cryopreserved as back-up in all patients. The numbers of LK needed to complete the whole procedure were: one (five patients), two (six patients) and three or more (six patients). The recovery of NC after the first cycle of purging was 81% (range 68.5-91.4). Nonspecific cell loss was 19% (2.8-35.1), most of this during the first cycle of separation (median 16.4%). Cell viability before and after purging was 98% (range 90-99) and 97% (range 89-99).
In the final purged BM and PBPC products a correlation was found between CD34 + cells/kg and CFU-GM/kg (r = −0.85, P Ͻ 0.0005). 
Purging efficiency by flow cytometry BM vs PBPC:
Purging efficiency as determined by the reduction in the total number of target antigen-positive cells measured by flow cytometry was Ͼ1.62 log (0.96-Ͼ2.67) on BM and Ͼ1.02 log (0.14-Ͼ1.6) on PBPC (P = 0.001).
One vs two cycles:
The log of target cell depletion (for both BM and PBPC) was Ͼ1.04 (0.15-Ͼ2.21) and Ͼ1.18 (0.14-Ͼ2.67) after the first and second course of immunomagnetic purging, respectively (P = 0.001).
Four vs five MoAb:
In nine cases, all of them from PBPC, four instead of five MoAb were used. The log of target cell depletion in PBPC tended to be higher with the use of five (eight cases) vs four (nine cases) MoAb: Ͼ1.03 (0.14-Ͼ1.6) vs Ͼ0.75 (0.28-Ͼ1.18), respectively, although the differences were not significant.
Purging efficiency by PCR detectable lymphoma cells
All purging procedures were assessed for bcl-2 translocation by PCR in the initial, in the first cycle absorbed (positive) and in the final (negative) cellular fraction. Results are shown in Figure 1 . Eighty-three of 87 samples were evaluable for PCR in all the above mentioned fractions. Two out of 12 patients (16.6%) and 6/16 (37.5%) were PCR positive in BM and PBPC harvests, respectively. Therefore, 28.5% of fresh samples had a PCR-amplified signal. In the final purged products, no PCR signal could be detected in 22/27 (81.4%) evaluable samples. PCR performed in the first-cycle cellular fraction containing IMBtarget cell complexes resulted in PCR+ products in 12/28 samples (42.8%). With the use of four MoAb, from 5/9 samples that were PCR+ in the initial and/or absorbed Data for hematological engraftment are shown in Table 2 .
Recipients of autologous PBPC had a faster ANC Ͼ0.5 × 10 9 /l recovery (median 14 days; 95% confidence interval (CI) = 12.16) than recipients of autologous BM (median 21 days; (13.29)) as shown in Figure 2 (P = 0.01). Similarly, platelet recovery was significantly faster with PBPC (median 14 days; (12.16)) than with BM transplants (median 41 days; (25.57)) as shown in Figure 3 (P = 0.001). For autologous PBPC transplants, there was a negative correlation between the number of CD34 + cells/kg infused and the days to neutrophil recovery (r = −0.59, P = 0.02). Those patients receiving a median of 7.3 × 10 6 (range 6.5-16.4) CD34 + cells/kg (n = 7) had a median time to granulocyte engraftment of 12 days (11.13) (range 10-17) as opposed to 14 days (11.17) (range 12-31) for those patients transplanted with 4.3 × 10 6 (range 3.8-6.2) (n = 8) (P = 0.02) as shown in Figure 4 . These differences were not found when comparing platelet recovery between these two groups (median 14 days (9.19) and 12 (8.16), respectively, P = 0.5) ( Figure 5 ). No correlation was demonstrated between CFU-GM/kg infused and granulocyte or platelet recovery. When analyzing BM autografts, we could not find any correlation between NC/kg, CFU-GM/kg and CD34 + cells/kg infused and granulocyte or platelet recovery. However, when the whole series was analyzed, including all BM and PBPC transplants, both CD34
+ cells/kg and CFU-GM/kg infused were negatively correlated with granulocyte engraftment (r = −0.59, P = 0.003) and (r = −0.58, P = 0.01), respectively. These parameters also reached a significant correlation for platelet engraftment: CD34 + cells/kg (r = −0.44, P = 0.03), CFU-GM/kg (r = −0.49, P = 0.04).
Discussion
The results presented in this report show that our B cell immunomagnetic purging method is capable of obtaining a high level of lymphoma cell depletion in FL patients. The purging efficiency as measured by flow cytometry was higher than 1.62 and 1.02 log in BM and PBPC, respectively. We also found that a second cycle of purging added a statistically significant higher target cell depletion as compared with only one cycle, in agreement with our previous work with purging in ALL. 16 However, the limited number of target cells in the PBPC before and after purging as well as the limited and nonspecific flow cytometry analysis using our approach hindered a correct analysis of B lymphocyte contamination since in many samples it was below our limits of detection.
More interesting results could be obtained from the data of PCR analysis. In two out of 12 BM and six out of 16 PBPC harvests, bcl2 translocated lymphoma cells were detected by PCR. Thus, 28.5% of pre-purging samples were PCR+ which is similar to other reports. 6 The two BMpurged products remained PCR+ after purging but 50% of PBPC products became PCR negative. Interestingly, in 20% of the samples in which we were unable to detect malignant cells by PCR in the pre-and post-purging samples, the cellular fractions containing the IMB-target cell complexes were PCR+. This means that this purging strategy was highly effective and was able to concentrate enough tumor cells in the absorbed fraction to allow their detection by PCR. Therefore, in those samples the fresh cellular fraction was likely to be contaminated by malignant cells, although below our limit of detection by PCR. Overall, 42.8% of the samples were PCR positive in the fresh and/or absorbed cellular fraction and only 18.5% of them were positive in the purged product. Thus, 42% of patients were purged to PCR negativity. Several additional patients had a clear reduction in the intensity of the bcl2/IgH amplified band in the purged product as compared to the start and absorbed cellular fraction. This indicates that purging was efficient in the reduction of the tumor burden to some extent. Similar results have been reported by Gribben et al 14 using three MoAb and three cycles of complement lysis with a 3-6 log killing of tumor cell line and achieving a PCR bcl2 translocation-negative purged BM in 50% of patients with FL. A similar 'ex vivo' approach used by Johnson et al 28 was able to obtain a PCR-negative purged BM product in 14% of 29 patients with FL. The DanaFaber group 19 also compared the efficiency of lymphoma cell depletion in BM with complement-mediated lysis and IMB. Their results indicated that the latter method achieved a better tumor cell depletion. Similarly, Kvalheim et al 22 reported a tumor cell depletion of more than 5 logs with this methodology as judged by clonogenic assays in experimental models using a lymphoma cell line.
In our study, no significant association was found between disease status or BM infiltration by lymphoma cells at purging and the ability to deplete bcl2+ cells from BM or PBPC. Association between tumor bulk in BM and inability to purge detectable lymphoma cells by PCR was shown by Gribben et al, 14 who could purge only two out of 11 BM harvests from patients with more than 10% of BM infiltration. Similarly, Negrin et al 6 reported that patients with BM involvement at purging had a significant higher percentage of PCR+ purged BM products as compared with patients who were morphologically normal. Although our results show that purging efficacy tended to be better in patients in CR and without BM involvement by histology, most of our purging procedures were performed with PBPC and the contribution of BM involvement by lymphoma cells in effectiveness of PBPC purging remains to be determined.
Recovery of NC and CD34 + cells is also high and reproducible with this technique. Median yield of NC was of 59.3% and 77.2% in BM and PBPC products, respectively (P Ͻ 0.0005). The higher cell loss found in BM products was due to specific target cell loss since no differences were found in nonspecific cell loss between BM and PBPC. We also obtained a higher yield of CD34 + cells in PBPC than in BM-purged products (73.5% vs 56.1%, respectively, P = 0.001). BM harvests had a significantly higher percentage of CD34 + cells that co-expressed antigens in the B cell pool than PBPC. Thus, recovery of CD34 + cells was expected to be lower when purging B cells from BM products. These data are also in agreement with the results from other groups. 22, 23 The BM-and PBPC-purged products showed normal in vitro growth as determined by clonogenic assays, indicating that immunomagnetic purging did not negatively affect progenitor cell proliferation.
Purged BM and PBPC products showed normal in vivo proliferation capacity. Engraftment was complete and fast in all but one evaluable patient. Median time to reach an ANC Ͼ0.5 × 10 9 /l was 21 and 14 days for BM and PBPC autografts, respectively. Platelet counts over 20 × 10 9 /l were achieved on day 41 and 14 with BM and PBPC autografts, respectively. These figures are comparable to those observed after transplantation of unmanipulated products containing similar numbers of LDCs or CD34 + cells. [29] [30] [31] In this series the number of CD34 + cells/kg infused with PBPC-purged products negatively correlated with the speed of neutrophil recovery after transplantation (r = −0.59, P = 0.02). Granulocyte engraftment was 2 days shorter for those patients transplanted with a median of 7.3 × 10 6
CD34
+ cells/kg as compared to those transplanted with 4.3 × 10 6 CD34 + cells/kg (12 vs 14 days, respectively, P = 0.02). These data are also similar to other series that reported a faster neutrophil recovery with the infusion of higher numbers of CD34 + cells. 32, 33 In PBPC autografts, the minimum number of CD34 + cells/kg infused was so high that it did not allow us to appreciate significant differences in platelet recovery. No discernible effect on platelet recovery in patients receiving high numbers of CD34 + cells/kg has been shown by others. 33 Also, the absence of a significant correlation between engraftment and the number of progenitor cells infused in the BM setting may result from the limited number of patients autografted. However, platelet and neutrophil recovery significantly correlated with both CD34
+ cells/kg and CFU-GM/kg infused, when the whole series was analyzed, which includes a broader range of progenitors.
From the data presented in this report, we cannot conclude which progenitor cell source is better in terms of purging. PBPC are increasingly replacing BM as the source of progenitor cells for autologous transplant because it facilitates progenitor cell collection, decreases the time to granulocyte and platelet engraftment, and is associated with decreased procedure-related toxicity. 34 It has also been reported that there are no differences in the concentration of bcl-2/IgH rearranged cells between BM and PBPC using a nested quantitative competitive PCR technique. 10 However, the higher cell number in PBPC than in BM grafts, might suggest a higher level of contamination by lymphoma cells. Despite its efficiency, the main limitation of PBPC purging with this immunomagnetic method is the higher cost of the procedure, since a mean of 10 times more IMB are required than when BM is used. However, the fast neutrophil and platelet engraftment showed with PBPC in relation to BM predict potential benefits in terms of numbers of red blood cell and platelet transfusions and time to discharge from hospital. 35 In summary, our data demonstrate that immunomagnetic purging in BM as well as in PBPC is a safe and reproducible procedure and that the purged products are capable of normal engraftment after autologous transplantation. It is also able to obtain a substantial degree of lymphoma cell depletion as shown by the absence of bcl2+ cells in nearly half of the purged products using a very sensitive PCR technique. Although no conclusive evidence exists showing a clinical benefit of purging, the main objective of a purging technique in autologous products should be to obtain tumor-free products as assessed by the use of a sensitive tumor detection method. Although efficient, in our method there still is a significant proportion of bcl2+ products by PCR after purging. In this sense, CD34
+ enrichment in combination with tumor cell depletion is expected to achieve even higher levels of purging. Pre-clinical and clinical studies are ongoing with this latter approach in our laboratory.
